Skip to main content

Table 8 Research of REDD1 in different tumor types

From: Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma

First author Journal (year) Results Function of REDD1 Tumortype
Horak P Proc Natl Acad Sci U S A. (2010) [4] • REDD1 inactivation induces ROS dysregulation and consequent HIF-1α induction that promotes tumorigenesis.
• Loss of REDD1 induces a hypoxia-dependent increase in proliferation and anchorage-independent growth in vitro.
• Breast carcinomas exhibit silencing of REDD1 expression compared with normal epithelia.
Suppresses tumorigenesis breast cancer
Kucejova B Mol Cancer Res. (2011) [18] • REDD1 is highly expressed in VHL-deficient clear-cell renal cell carcinoma (ccRCC).
• Mutations in REDD1 may contribute to ccRCC development.
possibly a tumor suppressor in sporadic ccRCC. ccRCC
Jin HO Cancer Lett. (2013) [19] • Sustained overexpression of Redd1 leads to mTORC1 inhibition and to consequent Akt activation that is involved in cell survival.
• Akt phosphorylation, which consequent to mTORC1 inhibition and sustained REDD1 overexpression, plays a role in cell survival and resistance to chemotherapeutic drugs.
/ lung cancer cells.
Zeng Q Clin Cancer Res. (2018) [20] • The significant increase of REDD1 expression is detected in bladder urothelial carcinoma(BUC) tissue.
• REDD1 is an independent prognostic factor in BUC patients.
• Silencing REDD1 expression in T24 and EJ cells decreased cell proliferation, increased apoptosis, and decreased autophagy. The ectopic expression of REDD1 in RT4 and BIU87 cells had the opposite effect.
• Inhibited REDD1 expression sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant sarcoma model in vivo.
REDD1 is an oncogene.
Antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel
BUC